COMMUNIQUÉS West-GlobeNewswire

H.H.C. Group Successfully Completes URAC Monitoring Validation Review as Independent Review Organization

09/01/2025 - 16:02

ROCKVILLE, Md., Jan. 09, 2025 (GLOBE NEWSWIRE) -- H.H.C. Group (H.H.C), the leader in reducing healthcare costs by providing high-quality cost containment using claim negotiation, repricing and independent review [...]

Numab Therapeutics Announces Series C Extension to CHF 180 Million, Completing Oversubscribed CHF 50 Million Financing

09/01/2025 - 16:00

CHF 50 Million extension round co-led by Cormorant Asset Management, with participation from other existing investors Proceeds will be used to support the advancement of multiple first-in-class and best-in-class [...]

AscellaHealth Releases Q4 2024 Specialty & Rare Pipeline Digest™ Featuring Key Specialty Drug, Biosimilar, Cell and Gene Therapy Approvals

09/01/2025 - 16:00

BERWYN, Pa., Jan. 09, 2025 (GLOBE NEWSWIRE) -- AscellaHealth , a global partner delivering customizable solutions to support the specialty pharmaceutical industry, today launched its latest Specialty & Rare Pipeline [...]

Carestream’s Focus HD Detectors, DRX-Rise Mobile X-ray System Receive European Union CE Marking Approval

09/01/2025 - 15:30

ROCHESTER, N.Y., Jan. 09, 2025 (GLOBE NEWSWIRE) -- Carestream Health today announced today it received European Union CE Marking Approval for both its Focus HD Detectors and DRX-Rise Mobile X-ray System. “This is an [...]

CORRECTION -- Rapport Therapeutics Announces New Phase 1 Data, Further Supporting RAP-219's Transformative Potential for CNS Disorders

09/01/2025 - 15:12

BOSTON and SAN DIEGO, Jan. 09, 2025 (GLOBE NEWSWIRE) -- In a release issued under the same headline earlier today by Rapport Therapeutics, Inc. (Nasdaq: RAPP), please note the references to the AMPA-associated protein, [...]

BioLizard Welcomes Arjan van Manen as Commercial Director and Announces Presence at JPM Week in San Francisco

09/01/2025 - 15:00

Arjan van Manen joins BioLizard as Commercial Director, bringing over 20 years of commercial leadership experience in life sciences Meet BioLizard’s Arjan van Manen and CEO Liesbeth Ceelen at Biotech Showcase during JP [...]

Lyell to Highlight Vision for its Next-Generation CAR T-Cell Therapy Pipeline at 43rd Annual JP Morgan Healthcare Conference

09/01/2025 - 15:00

Accelerating IMPT-314 in large B-cell lymphoma; remain on track to initiate pivotal trial in the 3 rd line+ setting in 2025 and expect to initiate a pivotal trial in the 2 nd line by early 2026 Presenting additional [...]

Inmagene Reports Positive Topline Results of IMG-007, a Nondepleting Anti-OX40 Monoclonal Antibody with an Extended Half-Life, for the Treatment of Atopic Dermatitis

09/01/2025 - 15:00

A 4-week treatment with IMG-007 resulted in a mean reduction in eczema area and severity index (EASI) of 77% and EASI-75 response of 54%, at week 16 Durable inhibition of inflammatory markers was observed for up to 24 [...]

Cannabix Technologies Announces Key Hardware Advancements to Marijuana Breathalyzer Technology

09/01/2025 - 14:45

VANCOUVER, British Columbia, Jan. 09, 2025 (GLOBE NEWSWIRE) -- Cannabix Technologies Inc. (CSE: BLO) (OTC PINK: BLOZF) (Frankfurt: 8CT) (the “Company” or “Cannabix”) developer of marijuana and alcohol breath testing [...]

FYR Appoints Chris Howlett to its Board of Directors

09/01/2025 - 14:30

Appointment adds business, market and partner development expertise to FYR board Addition highlights FYR’s evolution into partner of choice for drugmakers seeking deep insights into disease and treatment response [...]

Alkeus Pharmaceuticals Announces New Positive Interim TEASE-3 Study Results Showing Gildeuretinol Prevented Disease Progression in Early-Stage Stargardt Patients

09/01/2025 - 14:30

Two additional TEASE-3 participants who recently completed 24 months of therapy showed no disease progression, consistent with prior results. A total of five patients have completed the 24-month study. Following the [...]

Hydreight Technologies Provides Shareholder Update on 2024 Milestones and 2025 Vision

09/01/2025 - 14:30

VANCOUVER, British Columbia and LAS VEGAS, Jan. 09, 2025 (GLOBE NEWSWIRE) -- Hydreight Technologies Inc. (“Hydreight” or the “Company”) (TSXV: NURS) (OTCQB: HYDTF) (FSE: SO6), a rapidly growing mobile clinical network [...]

Biosphere Launches UV Bioreactor to Transform Industrial Fermentation

09/01/2025 - 14:30

Following $8.8m seed round, Biosphere aims to slash biomanufacturing’s capital costs by more than 50% OAKLAND, Calif., Jan. 09, 2025 (GLOBE NEWSWIRE) -- Biosphere , a startup developing advanced bioproduction systems, [...]

Ori Biotech Expands Team to Advance IRO Commercialization and Industry Partnerships

09/01/2025 - 14:30

Company Making Additions to Executive Team and Advisory Board to Support Significant Commercial Momentum LONDON, Jan. 09, 2025 (GLOBE NEWSWIRE) -- Oribiotech Ltd (Ori), a leader in cell and gene therapy (CGT) [...]

IO Biotech Completes Enrollment in Phase 2 Trial of its Investigational, Off-the-shelf Therapeutic Cancer Vaccine, IO102-IO103, as Neoadjuvant/Adjuvant Treatment for Patients with Resectable Melanoma or Head and Neck Cancer

09/01/2025 - 14:05

-- Enrollment Completed Ahead of Schedule -- -- Initial Data Expected in 2025 -- NEW YORK, Jan. 09, 2025 (GLOBE NEWSWIRE) -- IO Biotech (Nasdaq: IOBT), a clinical-stage biopharmaceutical company developing novel, immune [...]

Amwell® divests virtual psychiatric care business to Avel eCare in all-cash transaction

09/01/2025 - 14:00

Divestment of Amwell Psychiatric Care intended to focus product portfolio on key growth initiatives Company reiterates guidance for 2024 BOSTON, Jan. 09, 2025 (GLOBE NEWSWIRE) -- Amwell ® (NYSE: AMWL), a global leader [...]

Frontier Medicines Announces FMC-220, the First Covalent p53 Y220C Activator Development Candidate, with Best-in-Class Potential

09/01/2025 - 14:00

FMC-220 is a first-in-class covalent activator of p53 Y220C designed to address potency and tolerability challenges of non-covalent approaches In preclinical studies, FMC-220 demonstrated unprecedented potency and [...]

RAPT Therapeutics to Present at the 43rd Annual J.P. Morgan Healthcare Conference

09/01/2025 - 14:00

SOUTH SAN FRANCISCO, Calif., Jan. 09, 2025 (GLOBE NEWSWIRE) -- RAPT Therapeutics, Inc. (Nasdaq: RAPT), a clinical-stage, immunology-based biopharmaceutical company focused on discovering, developing and commercializing [...]

Daré Bioscience to Participate in the Women’s Health Series at the 43rd Annual J.P. Morgan Healthcare Conference

09/01/2025 - 14:00

The panel will discuss the value proposition for investing in women’s health. J.P. Morgan is hosting a three-panel women’s health series at this year’s conference to highlight the importance of innovation and growing [...]